Carl H. June, M.D. Research Group

University of Pennsylvania

Can engineered T cells be reprogrammed to eliminate cancer while maintaining patient safety? The June Lab focuses on ex vivo T-cell engineering to create cell-based therapies for cancer and HIV. The laboratory is primarily responsible for developing new CARs and new vectors for current and proposed indications and for translating laboratory insights into clinical trials. Researchers apply genetic engineering and vector design to produce CAR T cells and related cellular immunotherapies for clinical testing. The lab integrates translational research to move biologically-focused ideas into safe, effective cancer therapies.